All In Biotech

Drug Trial Radar · NCT07076290

A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Apr 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Rise Therapeutics LLCIndustry
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)
  • COPD Exacerbation
  • COPD Exacerbation Acute

Interventions

  • R-3750Drug

    R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the treatment-related adverse events of R-3750Time frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.